Generation Bio

Name

Generation Bio

Legal name

Generation Bio Co.

Website

https://generationbio.com

Company type

Private

Founded year

2020

Operating status

Acquired

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Genetic Medicine

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods) (HLAAACAC)

Keywords

• Non-viral gene therapy
• Lipid nanoparticle delivery
• Genetic medicines
• Nucleic acid therapeutics
• Cell-targeted therapeutics

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Others

Revenue model

1. Therapeutic Development and Licensing: Pre-revenue clinical-stage company developing gene therapies. Revenue model based on potential future licensing deals and platform monetization through the XOMA acquisition.

Go-to-market motion1 record

Marketing channels1 record

Core offering

Generation Bio developed a non-viral genetic medicines platform built on a proprietary cell-targeted lipid nanoparticle (ctLNP) delivery technology. The platform was designed to deliver siRNA, mRNA, and iqDNA nucleic acid therapies to specific tissues for the treatment of genetic diseases, with a focus on liver diseases, eye conditions, and autoimmune diseases.

Product overview

Generation Bio developed a non-viral genetic medicines platform centered on its cell-targeted lipid nanoparticle (ctLNP) delivery technology. The platform integrates multiple therapeutic modalities including siRNA for gene silencing, mRNA for protein expression, and iqDNA therapies. These technologies are designed to provide durable and redosable treatments for genetic diseases, with a focus on liver diseases, eye conditions, and autoimmune diseases. The ctLNP delivery platform offers advantages over traditional viral vector approaches by enabling targeted tissue delivery and repeat dosing. Generation Bio was acquired by XOMA Royalty Corporation in February 2026.

Differentiator

Problem solved

Functional benefit

Products and services

• Cell-Targeted Lipid Nanoparticle (ctLNP) Delivery Platform A proprietary non-viral delivery platform utilizing cell-targeted lipid nanoparticles to deliver siRNA and nucleic acid therapies to specific tissues and cell types, designed to provide durable and redosable treatments for genetic diseases and offering potential advantages over traditional viral vector approaches.
• siRNA Technology Gene-silencing technology that enables targeted suppression of specific genes, integrated with the ctLNP delivery platform for treating genetic diseases.
• iqDNA Therapies Novel non-viral genetic medicine approach developed for rare and prevalent diseases, extending the company's platform beyond original gene therapy technology.
• mRNA Therapies Non-viral genetic medicines leveraging messenger RNA for therapeutic protein expression, developed using the company's lipid nanoparticle delivery platform.

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• ModernacoreStrategic or Co-development Partner · 16 December 2025Generation Bio had a collaboration with Moderna. The acquisition by XOMA included contingent value rights tied to potential proceeds from the Moderna collaboration. CVRs entitle holders to potential payments from Moderna licensing milestones and future platform out-licensing or sales.

Scale indicators5 records

Recent moves5 records

Expansion highlights3 records

Broad incumbents

• BioNTech: BioNTech is a global leader in mRNA therapeutics and LNP delivery technology with oncology and infectious disease franchises. Its scale and platform breadth make it a broad incumbent comparable to Generation Bio on core LNP/nucleic acid delivery technology.
• Moderna: Moderna is the global leader in LNP-based mRNA therapeutics and was Generation Bio's strategic partner via the 2023 equity investment and later collaboration. Both companies leverage lipid nanoparticle delivery platforms for nucleic acid-based medicines, making them directly comparable on technology architecture and target indications (liver, rare disease).

Direct peers

• Beam Therapeutics: Beam develops base editing and other precision genetic medicines using both viral and non-viral delivery approaches. As a clinical-stage genetic medicines platform company pursuing liver and other tissue targets, Beam is comparable to Generation Bio in business model and therapeutic positioning.
• Alnylam Pharmaceuticals: Alnylam is the commercial leader in siRNA-based genetic medicines with approved products targeting liver-expressed genes. Generation Bio's ctLNP platform for siRNA delivery in liver indications competes directly with Alnylam's GalNAc-conjugated siRNA platform, making it the closest commercial-stage comparator.
• Intellia Therapeutics: Intellia develops in vivo CRISPR-based gene editing therapies with clinical programs in transthyretin amyloidosis and hereditary angioedema. As a clinical-stage genetic medicines company pursuing durable, single-dose cures, Intellia competes for the same liver-directed genetic disease market that Generation Bio targeted.
• Arcturus Therapeutics: Arcturus develops mRNA-based therapeutics using its STARR® self-amplifying mRNA platform combined with lipid nanoparticle delivery. Comparable to Generation Bio in modality (mRNA + LNP), therapeutic area focus, and clinical-stage development profile.
• Dicerna Pharmaceuticals: Dicerna developed GalNAc-conjugated siRNA therapies for liver-expressed targets before being acquired by Novo Nordisk. Comparable to Generation Bio's siRNA/liver strategy and serves as a relevant precedent for platform biotech M&A outcomes in this space.
• Arrowhead Pharmaceuticals: Arrowhead develops RNAi-based therapeutics using multiple delivery platforms including TRiM™ and lipid nanoparticles for liver and extrahepatic targets. It is a direct competitor to Generation Bio's ctLNP-delivered siRNA programs in hepatic and rare disease indications.

Emerging players

• Verve Therapeutics: Verve is developing in vivo base editing therapies for cardiovascular disease, with liver-directed LNP-delivered programs in early clinical development. Comparable to Generation Bio's ctLNP platform for liver-targeted genetic medicines, though focused specifically on cardiovascular indications.

Others

• Acuitas Therapeutics: Acuitas is a leading LNP technology platform provider whose delivery systems underpin Moderna's COVID-19 vaccine and other mRNA products. As a non-viral delivery infrastructure specialist, Acuitas is thematically comparable to Generation Bio's ctLNP platform on technology rather than competing commercially.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

• Xx.com/lifetimegeneTX
• LinkedInlinkedin.com/company/generationbio

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds5 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Generation Bio